We present the molecular landscape of pediatric acute myeloid leukemia (AML) and
characterize nearly 1,000 participants in Children's Oncology Group (COG) AML trials. The …

Overall survival (OS) of pediatric patients with acute myeloid leukemia (AML) increased in
recent decades. However, it remained unknown whether advances in first-line treatment …

Despite significant progress in the treatment of pediatric acute myeloblastic leukemia (AML),
relapse remains the commonest cause of death. Randomized ELAM02 trial questioned if …

The purpose of this study is to compare the efficacy and safety of combination therapy (HD-
ECM) including high-dose cytarabine in initial induction therapy with that of combination …

Background Bacterial infections in pediatric patients with leukemia are associated with
increased risks for morbidity and mortality. Few Recommendations have been made on the …

Acute leukemia is the most common childhood malignancy, accounting for almost 35% of all
childhood cancers. Acute myeloid leukemia (AML) represents 15–20% of pediatric acute …

Aminopeptidases, such as dipeptidyl peptidase-4 (DPP-4, CD26), are potent therapeutic
targets for pharmacological interventions because they play key roles in many important …

Background Patients with acute leukemia (AL) commonly present with abnormalities in
laboratory tests of blood coagulation. Coagulation abnormalities and disseminated …

Context: Acute lymphoblastic leukemia (ALL) shows substantial differences in clinical and
laboratory features and treatment responsiveness in different subgroups. Pediatric ALL< 2 …

Background: Childhood leukaemia survivors treated with haematopoietic stem cell
transplantation and total body irradiation (HSCT-TBI) have multiple risk factors for reduced …